| LOSS PER SHARE |
Note 17
— LOSS PER SHARE
Basic
and diluted loss per ordinary share is computed using the weighted average number of ordinary shares outstanding during the year. The
effects of all outstanding convertible redeemable preferred shares were excluded from the computation of diluted loss per share in each
of the applicable years as their effects would be anti-dilutive during the respective year.
Basic
and diluted loss per share for each of the years presented were calculated as follows:
| | |
For the Years Ended December 31, | |
| | |
2023 | | |
2024 | | |
2025 | |
| | |
RMB | | |
RMB | | |
RMB | | |
US$ | |
| Numerator: | |
| | |
| | |
| | |
| |
| Net loss | |
| (36,949,421 | ) | |
| (37,365,434 | ) | |
| (130,931,921 | ) | |
| (18,723,015 | ) |
| Accretion to redemption value of mezzanine equity | |
| (108,440,354 | ) | |
| (105,969,614 | ) | |
| (81,648,716 | ) | |
| (11,675,611 | ) |
| Less: Net income attributable to noncontrolling interests | |
| 1,057 | | |
| 25,878 | | |
| (1,520 | ) | |
| (217 | ) |
| Net loss attributable to the Pomdoctor Limited’s ordinary shareholders | |
| (145,390,832 | ) | |
| (143,360,926 | ) | |
| (212,579,117 | ) | |
| (30,398,409 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of shares outstanding – basic | |
| 6,310,198 | | |
| 6,310,198 | | |
| 9,680,622 | | |
| 9,680,622 | |
| Weighted average number of shares outstanding – diluted | |
| 6,310,198 | | |
| 6,310,198 | | |
| 9,680,622 | | |
| 9,680,622 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss per share – Basic: | |
| (23.04 | ) | |
| (22.72 | ) | |
| (21.96 | ) | |
| (3.14 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Loss per share – Diluted: | |
| (23.04 | ) | |
| (22.72 | ) | |
| (21.96 | ) | |
| (3.14 | ) |
|